{"id":"placebo-combined-with-ursodeoxycholic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ursodeoxycholic acid (UDCA) is a naturally occurring bile acid that works by decreasing cholesterol secretion into bile and increasing the solubility of cholesterol, thereby reducing the lithogenicity of bile. It also has cytoprotective and anti-inflammatory properties that may benefit hepatic and biliary tissues. The placebo control in this combination is used to assess the true efficacy of UDCA in the trial design.","oneSentence":"Ursodeoxycholic acid increases bile flow and reduces cholesterol saturation in bile to prevent gallstone formation and improve biliary function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:25.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gallstone prevention or dissolution (Phase 3 indication, specific condition not fully specified)"}]},"trialDetails":[{"nctId":"NCT05751967","phase":"PHASE3","title":"Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-22","conditions":"Primary Biliary Cholangitis","enrollment":150},{"nctId":"NCT06174402","phase":"PHASE2, PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Ying","startDate":"2023-08-21","conditions":"Primary Biliary Cholangitis","enrollment":184},{"nctId":"NCT05749822","phase":"PHASE2, PHASE3","title":"Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-17","conditions":"Primary Biliary Cholangitis","enrollment":104},{"nctId":"NCT04594694","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2019-10-02","conditions":"Primary Biliary Cholangitis","enrollment":75},{"nctId":"NCT06715319","phase":"PHASE3","title":"Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2021-10-09","conditions":"PBC","enrollment":100},{"nctId":"NCT03954327","phase":"PHASE2","title":"Combination Antiretroviral Therapy (cART) for PBC","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2021-03-01","conditions":"Primary Biliary Cholangitis","enrollment":37},{"nctId":"NCT00550862","phase":"PHASE2","title":"Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2007-10","conditions":"Liver Cirrhosis, Biliary","enrollment":165},{"nctId":"NCT01654731","phase":"PHASE3","title":"Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10-15","conditions":"PBC","enrollment":100},{"nctId":"NCT04956328","phase":"PHASE3","title":"Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2021-07-22","conditions":"Primary Biliary Cirrhosis","enrollment":120},{"nctId":"NCT00746486","phase":"PHASE3","title":"Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2009-02","conditions":"Primary Biliary Cirrhosis","enrollment":62},{"nctId":"NCT03521297","phase":"PHASE2","title":"Probiotics in PBC Patients of Poor Response to UDCA","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-01-20","conditions":"Primary Biliary Cholangitis (PBC)","enrollment":60},{"nctId":"NCT01904058","phase":"PHASE2","title":"Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"PBC, Primary Biliary Cirrhosis","enrollment":66},{"nctId":"NCT02026401","phase":"PHASE2","title":"Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"NGM Biopharmaceuticals, Inc","startDate":"2014-02","conditions":"Primary Biliary Cirrhosis","enrollment":45},{"nctId":"NCT01141296","phase":"PHASE2","title":"Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2011-04","conditions":"Primary Biliary Cirrhosis","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["UDCA 13-15mg/kg/d"],"phase":"phase_3","status":"active","brandName":"Placebo Combined With Ursodeoxycholic Acid","genericName":"Placebo Combined With Ursodeoxycholic Acid","companyName":"Xijing Hospital of Digestive Diseases","companyId":"xijing-hospital-of-digestive-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ursodeoxycholic acid increases bile flow and reduces cholesterol saturation in bile to prevent gallstone formation and improve biliary function. Used for Gallstone prevention or dissolution (Phase 3 indication, specific condition not fully specified).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}